RENOVORX INC (RNXT) Stock News

NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD

1.28 -0.01 (-0.78%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RNXT Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: RenovoRx, Inc.

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

25 days ago - By: Benzinga - Mentions: VNRX OGEN OVID XCUR ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: Yahoo Finance - Mentions: BBY HSCS KSCP BKNG ...

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

2 months ago - By: Benzinga

Earnings Preview For RenovoRx

2 months ago - By: Yahoo Finance - Mentions: OMI SMLR RDY HUM ...

Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition

2 months ago - By: Yahoo Finance - Mentions: SO OMI EPD PWR ...

PowerSecure Partners with Edged to Advance Eco-Friendly Data Centers Across the Country

2 months ago - By: Zacks Investment Research - Mentions: AUNA

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

2 months ago - By: RenovoRx, Inc.

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

2 months ago - By: RenovoRx, Inc.

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

3 months ago - By: RenovoRx, Inc.

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

3 months ago - By: RenovoRx, Inc.

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

3 months ago - By: RenovoRx, Inc.

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

3 months ago - By: RenovoRx, Inc.

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

4 months ago - By: RenovoRx, Inc.

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

4 months ago - By: RenovoRx, Inc.

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

4 months ago - By: RenovoRx, Inc.

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

4 months ago - By: RenovoRx, Inc.

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

4 months ago - By: RenovoRx, Inc.

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

4 months ago - By: RenovoRx, Inc.

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

5 months ago - By: RenovoRx, Inc.

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

5 months ago - By: RenovoRx, Inc

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

5 months ago - By: RenovoRx, Inc.

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

6 months ago - By: RenovoRx, Inc.

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

6 months ago - By: RenovoRx, Inc.

RenovoRx Announces Proposed Public Offering

6 months ago - By: RenovoRx, Inc.

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

7 months ago - By: RenovoRx, Inc.

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

7 months ago - By: RenovoRx, Inc.

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

8 months ago - By: RenovoRx, Inc.

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System